Indoco Remedies: Indoco's Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical…

What happened

Indoco Remedies (INDOCO) filed a disclosure with the exchanges on 27 October 2026 at 03:37 PM titled "Indoco's Clinical Research Orgainsation - AnaCipher receives approval from ANVISA Brazil for its clinical and bioanalytical facilities".

Company snapshot

Indoco Remedies is a small-cap company, with a market value of about ₹2,091 crore.

The stock last traded at ₹226.5, against a 52-week range of ₹162.2–₹288 (21.4% below the high).

Before this filing the shares had moved −9.8% over the month and −8.7% over three months. Average daily turnover over the last 20 sessions was about ₹33.42 crore.

Promoters held 58.86% at the end of Q1 FY27. Foreign institutions owned 1.27% and domestic institutions 17.68%.

What history shows

This is not the company's first approval disclosure: BCEIE has 1 earlier filing of this kind on record since May 2026.

Market-wide, 1,520 approval filings with an impact score of 50 or more saw an average next-day move of +0.1%, with 47% rising.

Past reactions describe what happened before; they are not a forecast.

What to watch

• 27 October 2026: Board meeting — Financial Results.

In the news

Recent coverage elsewhere (links open the original publisher):

• Indoco Remedies Limited Estimates – NSE:INDOCO — TradingView, 25 Oct 2026
• Indoco Remedies Shares Slid Even Though It Turned A Profit — Simply Wall Street, 27 Oct 2026
• Indoco Remedies Q2 Results: Company swings to ₹19.5 crore profit, revenue rises 7.4% — Business Upturn, 27 Oct 2026
• Indoco Remedies Share Price Quietly Does Something Most Mid-Cap Pharma Stocks Won’t — ABC Money, 15 Oct 2026
• Pharma sector stocks today, October 15: Panacea Biotec falls 1.75%, Wockhardt down 1.12%, Indoco Remedies down 1% — Business Upturn, 15 Oct 2026

Source

• Exchange filing (PDF)